Qomel Company Limited (9600.SR) operates as a healthcare provider in Saudi Arabia, offering ophthalmology services including vision examination, vision correction and eye surgeries; dental services; wound care services; pharmaceuticals encompassing specialized medications through distribution agreements with multinational companies; and medical supplies and devices. The company maintains headquarters in Riyadh with sales offices and SFDA-compliant warehouses in Jeddah and Dammam, focusing on institutional and government customers across the Kingdom. Founded in 2007, Qomel provides additional healthcare solutions such as pharmacovigilance, regulatory affairs, sales and marketing support; and advances into pharmaceutical manufacturing via its subsidiary Qomel Manufacturing, which secured SAR 50.7 million financing from the Saudi Industrial Development Fund for a new plant targeting specialty products with production slated by end-2025. Recent developments include non-binding memoranda of understanding signed on September 3, 2025, with National Unified Procurement Company (NUPCO) and UK firms Nova Laboratories Limited and Waymade PLC to enhance supply chain efficiency and product registration priority in Saudi Arabia; plus prior June 2025 contracts with NUPCO totaling SAR 30.94 million. Qomel listed shares on the Nomu parallel market and pursues expansion into private sector sales amid growing demand for chronic disease treatments.